During the past decade, Immunologisches Zentrum Vogelsang-Gommern GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Immunologisches Zentrum Vogelsang-Gommern GmbH" are "Ankylosing Spondylitis" (1 trials), "Arthritis, Psoriatic" (1 trials) and "Arthritis, Rheumatoid" (1 trials). Many other conditions were trialed in "Immunologisches Zentrum Vogelsang-Gommern GmbH" in a lesser frequency.

Most popular intervention types in "Immunologisches Zentrum Vogelsang-Gommern GmbH" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Guselkumab" (1 trials), "IL-17i" (1 trials), "Placebo" (1 trials), "Tofacitinib 10 mg" (1 trials) and "Tofacitinib 2 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Immunologisches Zentrum Vogelsang-Gommern GmbH" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Immunologisches Zentrum Vogelsang-Gommern GmbH". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Immunologisches Zentrum Vogelsang-Gommern GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Immunologisches Zentrum Vogelsang-Gommern GmbH, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".